A Phase 1 interventional study of TMC435 150 mg capsule and TMC435 150 mg oral suspension (20 mg/mL) in Healthy Volunteers, sponsored by Janssen R&D Ireland. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-25.
Sponsored by Janssen R&D Ireland · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate the relative bioavailability and the short-term safety and tolerability of TMC435 following administration of 3 single oral doses of 150 mg, given as different formulations in healthy adult participants. In addition, this study is to assess for the acceptability of the taste of both liquid formulations.
TMC435 is being investigated for the treatment of chronic hepatitis C infection. The current study is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (study medication is assigned by chance) study designed to assess the relative bioavailability and food effect of 2 liquid formulations of TMC435, currently being developed for potential pediatric use, compared to the Phase III 150 mg capsule. Also new capsule concept formulations will be investigated in comparison with the Phase III 150 mg capsule. The study will be performed in healthy adult participants and is divided over 3 panels. Participants will be randomized within a panel. Each participant will receive 3 different treatments according to a classical 6-sequence, 3-period Williams design. In Panel 1 and Panel 2, a single oral dose of 150 mg TMC435 oral suspension respectively with other strength will be compared with the capsule used in Phase III. In Panel 3, two different capsule concept formulations will be compared with the capsule used in Phase III. In panels containing the liquids, formulations will be compared under fasted and fed conditions to investigate the food effect. In all treatments, the participants will receive medication on Day 1 of each treatment. There will be a washout period of at least 7 days between subsequent treatments. The main focus of the trial is the pharmacokinetic characteristics of all formulations (level-profile of TMC435 over time in the blood stream). This evaluation requires multiple blood samples from Day 1 till Day 4 in each treatment. Safety assessments (blood and urine tests, blood pressure, pulse, electrocardiogram, and physical examination) will follow a different schedule and will be evaluated from signing of the Informed Consent Form onwards until the last trial-related visit throughout the study.
Janssen R&D Ireland is the lead sponsor of 31 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
Drug: TMC435 150 mg capsule
Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
Drug: TMC435 150 mg oral suspension (20 mg/mL)
Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
Drug: TMC435 150 mg oral suspension (20 mg/mL)
Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
Drug: TMC435 150 mg capsule
Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
Drug: TMC435 150 mg oral solution (10 mg/mL)
Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
Drug: TMC435 150 mg oral solution (10 mg/mL)
Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
Drug: TMC435 150 mg capsule
Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
Drug: TMC435 150 mg capsule concept K
Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
Drug: TMC435 150 mg capsule concept L
single oral dose of 150 mg TMC435 150 mg capsule
Also known as: TMC435
single oral dose of 150 mg TMC435 oral suspension
Also known as: TMC435
single oral dose of 150 mg TMC435 oral solution
Also known as: TMC435
single oral dose of 150 mg TMC435 capsule concept K
Also known as: TMC435
single oral dose of 150 mg TMC435 capsule concept L
Also known as: TMC435
Comparing the bioavailability of oral solution and oral suspension formulation with the capsule formulation of TMC435 (fed state)
Comparing the rate and extent of absorption (bioavailability) of 2 different liquid formulations (oral suspension \[150 mg ie, 20 mg/mL\] and oral solution \[150 mg ie, 10 mg/mL\]) versus capsule formulation (150 mg) of TMC435, after a high-fat breakfast (fed state)
Time frame: 4 days
Comparing the bioavailability of oral solution and oral suspension formulation of TMC435 in fed and fasted state
Comparing the rate and extent of absorption (bioavailability) of 2 different liquid formulations (oral suspension \[150 mg ie, 20 mg/mL\] and oral solution \[150 mg ie, 10 mg/mL\]) of TMC435 in fed state (high-fat breakfast) versus fasted state
Time frame: 4 days
Comparing the bioavailability of concept K capsule and concept L capsule formulation with the capsule formulation of TMC435 (fed state)
Comparing the rate and extent of absorption (bioavailability) of 2 different capsule formulations (concept K capsule \[150 mg\] and concept L capsule \[150 mg\]) versus capsule formulation (150 mg) of TMC435 after a high-fat breakfast (fed state)
Time frame: 4 days
Number of participants with adverse events
Adverse events, abnormal clinical laboratory findings, abnormalities assessed in vital signs examination, physical examination, ECG measurements were evaluated for safety and tolerability during the study
Time frame: 18 days
Acceptability of taste assessed by taste questionnaires
Taste Questionnaires used to assess taste acceptability of oral suspension and solution of TMC435 under fasted conditions. Taste Questionnaire for adults: participant had to select appropriate choice (None, Weak, Moderate, Strong) for 3 different types of tastes "Sweetness, Bitterness, Flavour" and also select appropriate choice (Bad, Amost acceptable, Acceptable and Good) for the Overall taste. For pediatric participants: fill the visual analog scale by selecting appropriate choice (Dislike it very much, Dislike it a little, Not sure, Like it a little and Like it very much)
Time frame: Day 1 of Treatment B and E
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen R&D Ireland